US 12,364,749 B2
RSV F protein mutants
Ye Che, Niantic, CT (US); Philip Ralph Dormitzer, Sherborn, MA (US); Alexey Vyacheslavovich Gribenko, New City, NY (US); Luke David Handke, Nyack, NY (US); Avvari Krishna Prasad, Chapel Hill, NC (US); Xiayang Qiu, Mystic, CT (US); Mark Edward Ruppen, Cresco, PA (US); Xi Song, Waterford, CT (US); Kena Anne Swanson, Pearl River, NY (US); Srinivas Kodali, Hillsborough, NJ (US); Xin Xu, Mahwah, NJ (US); Kariann Sweeney Efferen, Stamford, CT (US); Ping Cai, New City, NY (US); Kristin Rachael Tompkins, Garrison, NY (US); and Lorna Del Pilar Nunez, Briarcliff Manor, NY (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Mar. 29, 2023, as Appl. No. 18/192,352.
Application 18/192,352 is a division of application No. 17/060,944, filed on Oct. 1, 2020, abandoned.
Application 17/060,944 is a division of application No. 16/242,799, filed on Jan. 8, 2019, granted, now 10,821,171, issued on Nov. 3, 2020.
Application 16/242,799 is a division of application No. 15/896,871, filed on Feb. 14, 2018, granted, now 10,238,732, issued on Mar. 26, 2019.
Application 15/896,871 is a division of application No. 15/385,611, filed on Dec. 20, 2016, granted, now 9,950,058, issued on Apr. 24, 2018.
Claims priority of provisional application 62/421,184, filed on Nov. 11, 2016.
Claims priority of provisional application 62/387,270, filed on Dec. 23, 2015.
Prior Publication US 2023/0218738 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/155 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C07K 14/135 (2006.01); C12N 7/00 (2006.01); C12N 15/01 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/155 (2013.01) [A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/575 (2013.01); C07K 2319/02 (2013.01); C07K 2319/21 (2013.01); C07K 2319/22 (2013.01); C07K 2319/40 (2013.01); C07K 2319/70 (2013.01); C07K 2319/735 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18571 (2013.01)] 18 Claims
 
1. A method of preventing Respiratory Syncytial Virus (RSV) infection in a human infant comprising administering to a pregnant woman an effective amount of a pharmaceutical composition comprising (1) a mutant of a wild-type RSV F protein and (2) a pharmaceutically acceptable carrier, wherein the mutant comprises (a) a F1 polypeptide and a F2 polypeptide and (b) at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type RSV F protein, wherein the introduced amino acid mutation is a pair of cysteine mutations selected from the group consisting of: (i) 55C and 188C; (ii) 103C and 148C; and (iii) 142C and 371C, and wherein amino acid positions are numbered according to SEQ ID NO:1.